EOLS

Evolus, Inc.

EOLS | $11.49 -0.61% -0.61% 350K

(0.0% 1d) (-16.4% 1m) (26.0% 1y) (0.0% 2d) (-2.9% 3d) (-3.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 665,772,217
http://www.evolus.com
Sec Filling | Patents | 235 employees

(United States) Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

aesthetic brands treatment

Drugs

Jeuveau (Prabotulinum Toxin Type A)

add to watch list Paper trade email alert is off

Press-releases

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| -4.32% | O: -1.49% H: 0.0% C: 0.0%
jeuveau publication for study

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| -18.05% | O: 7.96% H: 0.13% C: -7.77%
million offering

Evolus Announces Results from European Head-to-Head Filler Trial
Published: 2024-03-01 (Crawled : 14:30) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| -22.25% | O: 0.0% H: 1.69% C: 0.54%
trial results

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| -18.4% | O: 0.92% H: 3.86% C: 1.96%

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
Published: 2023-11-07 (Crawled : 00:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| 44.67% | O: 0.38% H: 2.5% C: 1.0%
jeuveau financial results

“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
Published: 2023-11-06 (Crawled : 18:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| 45.4% | O: -0.13% H: 1.26% C: 0.63%
jeuveau meeting

Evolus to Participate in November Investor Conferences
Published: 2023-11-01 (Crawled : 15:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| 51.71% | O: 0.13% H: 0.79% C: 0.53%

Evolus to Report Third Quarter 2023 Results
Published: 2023-10-25 (Crawled : 14:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| 45.21% | O: -0.63% H: 1.14% C: -1.27%
report results

Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
Published: 2023-10-25 (Crawled : 14:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| 45.21% | O: -0.63% H: 1.14% C: -1.27%
meeting phase 2

Global Facial Injectable Market Analysis Report 2023-2028: New Product Launches, Increased Male Aesthetics, and Emerging Markets Driving Growth
Published: 2023-09-06 (Crawled : 10:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 13.9% | O: -0.1% H: 0.0% C: 0.0%
RVNC | $3.77 -0.53% -0.53% 1.6M

Health Technology

| -78.39% | O: -0.46% H: 1.38% C: -2.87%
EOLS | $11.49 -0.61% -0.61% 350K

Health Technology

| 18.5% | O: 0.41% H: 0.92% C: -0.1%
report global growth market

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001570562-24-000057	4	2024-03-29	2024-03-27	Sell	S	6236	689614
0001570562-24-000055	4	2024-03-21	2024-03-19	Sell	S	27603	372288
0001570562-24-000054	4	2024-03-21	2024-03-19	Sell	S	5672	154201
0001570562-24-000053	4	2024-03-21	2024-03-19	Sell	S	96566	695850